Chris Bahl ^UDM

Chris Bahl leads AI Proteins as its President. The Boston-based biotech company is innovating in protein therapeutics using AI-based design and a high-throughput discovery platform. AI Proteins specializes in creating novel proteins for specific therapeutic applications, aiming to develop cost-effective, specific, and potentially orally deliverable proteins, and accelerating the development of therapeutic candidates.